#ckd

Your Other Family Doctor

@yourotherfamilydr.bsky.social

5 hours ago

#cats #catsky #CatsOfBlueSky #CKD #kidneys #veterinary #vetmed #vetsky #healthcare #medical #caregivers

Patricia Kefalas Dudek (Patti)

@patriciadudek.bsky.social

11 hours ago

Previous COVID-19 infection may raise the risk of kidney disease, including acute kidney injury and chronic kidney disease, according to new research.

🔗 www.thecardiologyadvisor.com/news/previous-covid-19-t...

#COVID19 #KidneyHealth #CKD #PublicHealth

@gelliottservices.bsky.social

1 day ago

#fridayfit & Travel London>Midlands #indoor #outdoor #spring 🌸 #active www.gelliottservices.com Lupusfit™️ #freelance #mind #body #yoga #fitness #health #wellbeing #muscle #tone #strength #stretch #heart #exercise #goals #maintenence #Motivation General & #Lupus #raynauds #CKD #advocate #awareness

Duke OPSD

@dukeopsd.bsky.social

2 days ago

We recognize Annika Elstrom and her PUMP program experience. Mentored by Crystal Tyson, Annika worked with communities at risk for #CKD to improve study design—before launch. Learn more: mailchi.mp/duke/opsd-ma...
#Nephrology #CommunityEngagedResearch #PhysicianScientist #UndergraduateResearch

Your Other Family Doctor

@yourotherfamilydr.bsky.social

3 days ago

#cats #catsky #CatsOfBlueSky #vetmed #veterinary #veterinarymedicine #vetsky #CKD #kidneys #renal #health #resources #caregivers

@aprnworld.bsky.social

3 days ago

World Kidney Day: Don’t ignore silent kidney damage.
Learn evidence-based care for Chronic Kidney Disease with APRN World courses: Renal Dosing in CKD & CKD Clinical Guidelines for Management. Improve patient safety and outcomes.
#WorldKidneyDay #CKD #KidneyHealth #RenalCare #APRNWorld

European Association for the Study of Diabetes

@easdnews.bsky.social

3 days ago

Graphic for World Kidney Day on 12 March 2026 highlighting the link between diabetes and chronic kidney disease. The image shows a stylised illustration of kidneys and blood vessels on a blue background with the message: “Diabetes and chronic kidney disease are closely connected. Half of all chronic kidney disease cases are attributed to diabetes, yet most people living with the condition are unaware they have it.” The EASD (European Association for the Study of Diabetes) logo and website easd.org appear at the bottom.

Today on #WorldKidneyDay, we're highlighting 1 landmark trial presented at the 60th EASD Annual Meeting: the FLOW trial.

The 1st dedicated #kidney outcomes trial showing that semaglutide reduces major kidney #disease events by 24% in people with #T2D & #CKD.

📺👉 www.youtube.com/watch?v=NPJF...

@kireports.bsky.social

3 days ago

#CKD in Migrants: From Epidemiology to Challenges

https://doi.org/10.1016/j.ekir.2025.103726

#KIRReview

PICKED Project

@projectpicked.bsky.social

3 days ago

World Kidney Day 2026 🌍🩺

Kidney Health for All. Prevention. Early detection. Better outcomes.

#WKD2026 #KidneyHealthForAll #CKD #PICKEDproject

BavariaNephro

@bavarianephro.sueden.social.ap.brid.gy

3 days ago

Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease? ### ### _#NephJC Chat_ ** _Tuesday, March 10th 2026, 9 pm Eastern on Bluesky_** Clin J Am Soc Nephrol. 2026 Jan 2. doi: 10.2215/CJN.0000000969. Online ahead of print. # A Randomized Clinical Trial of Kidney Autologous Cell Therapy in Diabetic Kidney Disease Čižman, Borut; Butler, Emily L; Stavas, Joseph; Prakash, Rachita; Saad, Theodore; Silva, Arnold; Wooldridge, Thomas; Aqeel, Ahmed; Yan, Hongxia; Barysauskas, Constance M.; Culleton, Bruce **PMID: 41481370** More information Mar 9, 2026 Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease? Mar 9, 2026 This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease. Mar 9, 2026 Mar 9, 2026 REACT: El Resumen Visual Mar 9, 2026 Mar 9, 2026 Mar 9, 2026 REACT: The Visual Abstract Mar 9, 2026 Mar 9, 2026 _‘Failure is the simple opportunity to begin again, this time more intelligently’ Henry Ford_ # **Introduction** Around 850 million people around the world suffer from CKD; among them, 50% is due to diabetic kidney disease (DKD). For many decades, the only proven available therapy was renin-angiotensin system inhibitors (RASi). However, there has been a recent renaissance of therapies to slow DKD progression with newer molecules like sodium glucose transport inhibitors (SGLT2i), non-steroidal mineralocorticoid blockers (ns-MRAs), and glucagon-like peptide-1 receptor antagonists (GLP-1 RAs), creating the four pillars of DKD goal-directed medical treatment (GDMT) (Neuen et al, NDT, 2025). These drugs can slow the progression of kidney disease but not fully reverse it, indicating that there is still an unmet need in DKD. Recently, cellular therapy (i.e., regenerative medicine) has opened up new possibilities in CKD treatment, and this sci-fi-esque technology is now within reach. Mesenchymal stem cells (MSCs), present in bone marrow and other tissues, can generate any tissue depending on their surrounding milieu. MSCs are attracted to injured organs (due to cytokine signaling) and, therefore, are potential therapeutics for many chronic diseases (Farini et al, Stem Cells Int, 2014). Unfortunately, up until now, the ability of the kidney to repair glomerular injury was limited by the kidney’s low regenerative potential, and DKD led to an inevitable downward spiral to ESKD (Bussolati et al, Nat Rev Neph, 2016). Although initial studies with renal progenitor cells gave positive results in animal models of CKD, their short life span and lower potential to regenerate nephrons have limited their use in kidney disease. As we are aware, there are many types of kidney cells, and some do regenerate. Clinical medicine tells us that ATN and tubule regeneration is possible over a period of days to months. Surviving renal epithelial cells, even in the absence of renal progenitor cells, can regenerate the entire tubular system following acute tubular injury (Lin et al, J Clin Invest, 2005). In addition, animal models showed that selective renal cell injections can decrease the progression of kidney disease, halting the NfKB and TGF-ꞵ progressive damage (Stenvinkel et al, KI Rep, 2016); hence, renal autologous cell therapy (REACT therapy) has attracted interest for clinical use. REACT cells are collected through renal biopsy samples and grown in culture media before they are reinjected into the kidney directly (Stavas et al, Am J Neph, 2022). If a kidney transplant (whole organ) is the best renal replacement therapy, then is REACT (partial liquid transplant) the best preventative strategy for progressive DKD? # **The Study** ## **Methods** The REGEN-007 trial was a phase 2, multicenter, randomized, open-label trial designed to evaluate the safety and efficacy of rilparencel in adults with type 1 or type 2 diabetes mellitus and advanced CKD. The trial enrolled individuals aged 30 to 80 with an eGFR of 20 to 50 ml/min/1.73 m², a UACR between 30 and 5000 mg/g, and an HbA1c below 10%. View fullsize _Figure 1. Study design from_ _Cizman et al.__CJASN 2025_ **Inclusion and exclusion criteria** View fullsize **Preparation of Autologous Cells (Rilparencel) ** An ultrasound-guided or CT-guided renal biopsy specimen was taken and transported to the prokidney manufacturing unit. The harvested tissue undergoes enzymatic digestion and density gradient separation to isolate a heterogeneous population of renal epithelial lineage cells (SRCs). These cells are expanded _ex vivo_ for approximately four to six weeks under “good manufacturing practice” conditions before formulation into the final product rilparencel. The cell suspension is embedded in a thermolabile hydrogel carrier to facilitate cortical retention following injection. Unlike most investigational regenerative approaches in nephrology, which rely on systemically administered mesenchymal cells, rilparencel represents a locoregional autologous cell therapy. The therapeutic premise is that injection of renal lineage cells directly into the kidney cortex may exert regenerative or reparative effects through paracrine signaling, modulation of local inflammation, and antifibrotic pathways. Preclinical models have suggested that these SRC populations may contain epithelial progenitor-like cells derived from multiple nephron lineages, including tubular epithelial and glomerular epithelial cells, although the exact functional contribution of these cell populations in human kidneys remains uncertain. The required dose is calculated depending on the kidneys’ volume by MRI. For each gram of kidney, 3×106 cells are required for transfusion. The rilparencel concentration of 100×106 per 3 ml is sufficient for 100 g of kidney tissue. The final rilparencel product was injected percutaneously under CT guidance back into the patient’s kidney cortex. View fullsize _Renal autologous cell therapy- REACT figure from_ _Salybekov et al,__Front Cell Dev Biol, 2024_ **Randomization and endpoints ** The study’s primary efficacy endpoint was the change in the total (acute and chronic) slope of eGFR, calculated with the CKD-EPI 2009 equation, comparing the pre-injection period to the post-last injection period. Secondary efficacy endpoints included time to ≥40% eGFR decline, dialysis, renal or cardiovascular death, and composite renal outcomes. Safety endpoints encompassed biopsy-related complications, injection-related AEs, and product-related AEs. Analyses employed linear mixed-effects models for slope comparison and Kaplan-Meier methods for time-to-event outcomes. View fullsize Patients were randomized 1:1 into two treatment groups. * Cohort 1 (scheduled dosing): received two REACT injections—the first into 1 kidney and the second into the contralateral kidney approximately 3 months later. * Cohort 2 (triggered dosing): received one initial injection for the biopsied kidney and then evaluations every 3 months. A second injection was only administered if the patient met a “redose trigger," defined as an eGFR decline of ≥ 20% or a sustained UACR increase of ≥ 30%. If there were no triggers over a 15-month observation period following the first injection, then those patients would only receive a single injection. **Outcome Measurements, Safety Assessments, and Statistical Analysis ** Efficacy analyses were performed on the modified intent-to-treat population and safety analyses on the safety set. The primary efficacy endpoint—fall in eGFR slope—was made from a linear mixed model. View fullsize **Various subgroups** View fullsize **Primary safety endpoint:** The percentage of participants with procedure-related and investigational product-related treatment-emergent adverse events (AEs and TEAEs). **Secondary safety endpoint** : The percentage of participants with procedure-related death. **Determinants of 5-year and 2-year risk of ESRD** View fullsize **Funding Source ** Funding done by ProKidney (NASDAQ: PROK), a late-clinical-stage biotechnology company involved in autologous cell therapy which makes the product, and many of the authors (including first/last) are employees of the company. The company people did all the analysis and wrote the manuscript. # **Results** Between July 2021 and March 2023, 77 participants were screened across five clinical sites in the United States. Of these, 53 participants underwent randomization, with 27 assigned to Cohort 1 and 26 to Cohort 2. Overall, 45 participants completed study treatment (23 in Cohort 1 and 22 in Cohort 2). View fullsize _Figure 2. Participants screened and treated in study REGEN-007 (CONSORT Flow Diagram) from_ _Čižman_ _et al. CJASN 2026_ The study population reflected a typical cohort of patients with advanced diabetic kidney disease. The mean age**** was**** 60 years, and approximately 2/3rd**** of the trial participants were**** male. The majority had type 2 diabetes (78%), and the mean baseline eGFR was 33**** ml/min/1.73 m², indicating moderate to advanced CKD. Median albuminuria across the cohort was 421 mg/g. Most patients were on a RASi, around 30-40% were flozinated, with smaller numbers on a GLP1RA or an MRA. View fullsize _Table 1. Demographics and baseline characteristics from_ _Čižman_ _et al. CJASN 2026_ In the first cohort, most patients (24) received the two doses of rilparencel, while in the second cohort, 15/25 (~ 67%) needed a second injection because of eGFR decline of ≥ 20% or a sustained UACR increase of ≥ 30%. _Primary endpoint _ In Cohort 1, the annual change in kidney function in the preinjection period, as measured by the slope of eGFR, was −5.84 ml/min per 1.73 m² (95% CI, −7.97 to −3.70). In the period after the last injection, the annual change was −1.27 ml/min per 1.73 m² (95% CI, −3.97 to 1.43). The difference in the slope of eGFR between treatment periods was 4.57 ml/min per 1.73 m² (95% CI, 1.95 to 7.18). This represents a 78% improvement in the rate of eGFR decline for this group. View fullsize _Figure 3. Change in GFR slope, preinjection to post last infusion from_ _Čižman_ _et al. CJASN 2026_ In Cohort 2, the annual change in kidney function in the preinjection period, as measured by the slope of eGFR, was −3.40 ml/min per 1.73 m2 (95% CI, −5.03 to −1.77). In the period after the last injection, the annual change was −1.71 ml/min per 1.73 m2 (95% CI, −3.78 to 0.36). The difference in the slope of eGFR between treatment periods was 1.70 ml/min per 1.73 m2 (95% CI, −0.24 to 3.63). Subgroup analyses evaluated the primary endpoint across baseline characteristics (including CKD stage, body mass index, HbA1c level, albuminuria category, and background therapy with SGLT2i or GLP-1RA). No consistent interaction between baseline characteristics and treatment response was identified, although subgroup sample sizes were small. View fullsize _Supplement figure 1. Difference in slope of eGFR between pre and post injection from_ _Čižman_ _et al. CJASN 2026_ **Secondary outcomes ** Clinical events were relatively infrequent during follow-up. For the 3-component composite outcome (≥40% decline in eGFR, eGFR <15 ml/min/1.73 m², or kidney/cardiovascular death), events occurred in 7 participants (29%) in cohort 1 versus 5 participants (20%) in cohort 2. When a fourth component (increase in albuminuria ≥30%) was included, the four-component composite outcome occurred in 10 participants (42%) in Cohort 1 and 15 participants (60%) in Cohort 2. The median event-free time**** for this composite outcome in Cohort 2 was 17 months. View fullsize _Table 3. Secondary Outcomes from_ _Čižman_ _et al. CJASN 2026_ **Risk prediction** using the **Kidney Failure Risk Equation (KFRE, 8 variable equation)** suggested that kidney failure risk stabilized or improved in a proportion of participants following treatment. This was a prespecified endpoint of the study. At 12 months after the first injection: 29% (7 patients) Cohort 1 and 16% ( 4 patients) Cohort 2 had the same or a lower predicted risk of ESKD compared with baseline. At 18 months, this was unchanged for Cohort 1 and had increased further to 28% in Cohort 2 showing stabilization or reduction in their predicted risk of kidney failure. View fullsize _Table 2. Summary of 2-year and 5-year ESKD risk reduction. from_ _Čižman_ _et al. CJASN 2026_ Four patients in cohort 1 and two patients in cohort 2 experienced a > 40% sustained drop in eGFR at 30 days. Additionally, six patients in cohort 1 and twelve patients in cohort 2 had a > 30% increase in UACR sustained at 90 days. The actual change in UACR is not found in the paper or supplement. **Safety ** A total of 87 rilparencel injections were performed during the trial. Safety outcomes included adverse events related to 3 distinct components of the intervention: the kidney biopsy, the injection procedure, and the rilparencel itself. Procedure-related treatment-emergent adverse events occurred in 16 participants (33%). The most frequently reported events included injection site pain, renal hematoma, chills, headache, nausea. Six participants (12%) experienced product-related treatment-emergent adverse events, most of which were mild systemic symptoms such as nausea, dizziness, fatigue, or headache. View fullsize _Supplement table 3. Adverse events related to rilparencel, from_ _Čižman_ _et al. CJASN 2026_ Biopsy-related serious adverse events were reported in three participants and included subcapsular renal hematoma, acute kidney injury, and hematuria with hydronephrosis. One participant experienced a procedure-related subcapsular hematoma following injection. View fullsize _Supplement table 1. Adverse events related to kidney biopsy, from_ _Čižman_ _et al. CJASN 2026_ Importantly, no product-related serious adverse events and no procedure-related deaths were reported during the study. # **Discussion** In this phase 2, clinical trial, the use of the rilparencel was associated with a slower decline of eGFR compared to the previous trend, in patients with advanced DKD (GFR ~ 30s, UACR ~ 400 mg/g) and a pre-infusion eGFR loss of ~ 3.4 to 5.8 ml/min/1.73m2/year. This suggests that even in such advanced disease when we usually think fibrosis and a cycle of inexorably declining kidney function has set in, injecting renal autologous cells may promote recovery or suppress further damage. In this limited sample size and follow up, rilparencel also seems to be well tolerated and safe. **Strengths** For a phase 2 RCT, this was quite well done to demonstrate that the investigational agent has some promise of efficacy and is relatively safe. **Limitations** No placebo or sham procedure arm was included, a decision driven largely by the procedural nature of the intervention. Because all participants required an initial kidney biopsy to manufacture the cellular product, the investigators elected to compare outcomes against each participant’s historical disease trajectory rather than against a concurrently treated control group. Consequently, the trial’s primary efficacy analysis relied on within-subject slope comparison, contrasting the pre-intervention decline in kidney function- derived from historical eGFR measurements spanning up to 24 months- with the slope observed after treatment. While this design increases statistical efficacy in small exploratory studies, it introduces important interpretive challenges, including susceptibility to regression to the mean, the Hawthorne effect, variability in historical laboratory measurements, and changes in concomitant therapies over time. Though the authors report changes in KFRE, they do not report actual pre/post UACR to allow us to understand what drove this change. **Rilparencel or GDMT?** The present study allowed all baseline GDMT for DKD. During the study 80% of participants were on ACE inhibitors or ARBs, however only 37% were receiving SGLT2 inhibitors and 39% were on GLP-1 receptor agonists at baseline. This is actually better than average for most patients with DKD in the US. So the change in slope of eGFR attributed to rilparencel injections is not the full story. Even in 2021-2023, our optimal use of DKD medications remains low, and less than 10% of patients who would qualify for such GDMT are actually receiving all four medications. Hence, this was not a comparison that allows us to pit rilparencel against GDMT - since GDMT is already approved, one cannot do such a trial, and it is likely that in a phase 3 RCT many (or most) patients will be on GDMT as baseline standard of care. Nevertheless, as we have seen with reported data, it is almost possible to achieve remission - or bring eGFR down slope to a level expected for age-related decline - with full GDMT. GDMT also has other systemic benefits: reduction in blood sugars, blood pressure, obesity, and cardiovascular outcomes. It is unsure (and unlikely) that rilparencel would have such benefits. However, it represents a one or two shot intervention, with no ongoing pill burden. As uptake of GDMT medications increases, the need and effects of invasive procedures like REACT may be reserved for specific high risk DKD patients. Ultimately, the placebo-controlled phase 3 trial will determine whether rilparencel represents a new treatment option for patients with advanced type 2 diabetes mellitus and CKD. **What do other studies in this area show?** Various studies done with different cell lines in patients with AKI and CKD have been attempted, including stem cells and progenitor cells (Salybekov et al, Front Cell Dev Biol, 2024). These studies are not without controversy, and unfortunately incorporate many elements that may lead to bias in observations. Current research is hindered by several common limitations including: selection of patients at different CKD stages and different underlying etiologies of the CKD. Only a few trials, such as the REACT studies, specifically target diabetes-related cases. This is problematic because different etiologies can lead to distinct types of kidney damage, which may affect the efficacy of the treatment. In addition, there remains no consensus on the optimal cell dosage. The absence of a standardized dosing protocol may lead to inconsistent results across studies, difficulties in conducting meta-analyses and systematic reviews, and challenges in clinical implementation. Finally, the small sample sizes in many studies contribute to a lack of randomization, low statistical power, limited generalizability, a higher risk of false positives, and potential biases. View fullsize **Studies on autologous renal cells ** Of course there are many potential advantages of autologous cell therapy over RRT and even transplantation. Being able to regenerate one’s own tissue to prevent organ failure and/or exposure to lifelong immunosuppression would be preferable to many patients. Infusions are also less stressful than organ surgery on elderly patients who might not otherwise qualify for kidney transplantation. Various studies are in the pipeline; some are completed, some are recruiting, and the majority of the studies are in the US. View fullsize # **Conclusion** The REGEN-007 phase 2 trial suggests that autologous renal cell therapy may alter the trajectory of kidney function in patients with diabetic CKD. The magnitude of the reported change in eGFR slope is notable, although interpretation is limited by the open-label design, reliance on historical controls, and small sample size. Whether rilparencel ultimately becomes part of the DKD therapeutic armamentarium will depend on the results of the ongoing placebo-controlled phase 3 trial, which are needed to determine whether the observed signal translates into meaningful clinical outcomes such as delayed dialysis or improved survival. ### _Summary by _ _Dr Sai Vani Yellampalli_ _, Consultant nephrologist Kurnool Kidney Care_ ### _Dr Akshaya Jayachandran_ _ __Assistant Professor, Nephrology Christian Medical College & Hospital Vellore, Tamilnadu, India_ _NephJC Interns, Class of 2025_ Reviewed by _Cristina Popa_ _,__Brian Rifkin_ _,__Swapnil Hiremath_ ** _Header Image created by AI, based on prompts by_** ___Akshaya Jayachandran_ __

Could autologous cell therapy be a next option in treatment of diabetic kidney disease?

Read the excellent blog post at NephJC

http://www.nephjc.com/news/rilprencel-react

#CKD #Diabetes #DKD #Medicine #Nephrology #CellTherapy

サードニュース@相互フォロー100%

@new3rd.bsky.social

3 days ago

腎臓病の早期発見へ！「じんラボ」が新規会員登録キャンペーンを開催 「じんラボ」が世界腎臓デーに合わせて新規会員登録キャンペーンを開催。スマートウォッチなどが抽選で当たります。腎臓病の理解と早期発見を目指す試みです。

腎臓病の早期発見へ！「じんラボ」が新規会員登録キャンペーンを開催 #東京都 #世田谷区 #腎臓病 #CKD #じんラボ

「じんラボ」が世界腎臓デーに合わせて新規会員登録キャンペーンを開催。スマートウォッチなどが抽選で当たります。腎臓病の理解と早期発見を目指す試みです。

Thiard News@F4F

@newsen.bsky.social

3 days ago

Dr. Tsurukame Kitchen Offers Discounts to Support Kidney Care on World Kidney Day In honor of World Kidney Day, Dr. Tsurukame Kitchen launches a 10% discount campaign to alleviate the burdens of those managing renal diets.

Dr. Tsurukame Kitchen Offers Discounts to Support Kidney Care on World Kidney Day #Japan #Tokyo #CKD #Kuradashi #Dr._Tsurukame

Jo at MNB

@joatmnb.bsky.social

4 days ago

Is Finerenone the answer to type 1 diabetes CKD? | Medical News Bulletin Top docs say drug Finerenone reduces urinary ACR levels in type 1 diabetics. Learn more about treating diabetic kidney disease with MNB.

Have you heard? A phase 3 clinical trial just showed finerenone isn’t just for type 2 diabetics. The results of the FINE-One trial are in, and it’s good news for type 1 diabetics with chronic Kidney Disease. medicalnewsbulletin.com/kidney-disea... 🧪 🩺 #diabetes #ckd medsky

Kidney International

@kidneyint.bsky.social

4 days ago

The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

doi.org/10.1016/j.kint.2025.09.019

#MedSky #NephSky #OpenAccess #KDIGO #CKD #Obesity #kidneydisease

American Journal of Preventive Cardiology

@ajpcardio.bsky.social

4 days ago

🩺 Most adults with CKD are unaware, yet it raises CVD risk. Dual eGFR+UACR screening and early management improve outcomes.

🔗 https://ow.ly/CNsx50Ys37R

#PreventiveCardiology #CKD #CardiovascularRisk #Screening #HeartHealth #CardioSky #MedSky

Diary of a Kidney Warrior

@diaryofakidneyw.bsky.social

4 days ago

Slide emphasising that health is more complex than a number on a scale. Dee Moore explains that conversations about weight and health are more complex than a single number such as BMI. Educational content about kidney disease and transplant eligibility.

Call-to-action slide encouraging viewers to share the post with someone in the kidney community. Promotes the podcast episode “Weight, Dialysis and Kidney Transplant Eligibility – Beyond the Scale (Part 1)” from Diary of a Kidney Warrior Podcast, available on YouTube, Spotify, Apple Podcasts and Podbean in partnership with Kidney Care UK.

Weight and health are far more complex than a single number.

If you’d like to hear the full conversation with Dr Adrian Brown on BMI, dialysis and transplant eligibility:

kidneycareuk.org/get-support/...

#KidneyTransplant #CKD #obesity
#diaryofakidneywarriorpodcast #BMI #dialysis #weightloss

Nephrology Times

@nephtimes.bsky.social

4 days ago

Is It Time for Universal CKD Screening? | Docwire News With the burden of chronic kidney disease (CKD) on the rise, is it time to consider universal screening, or continue with a targeted strategy to prioritize high-risk populations?

🔗 www.docwirenews.com/post/is-it-t...
The cover story of our current print issue weighs the question: Should we implement universal screening for CKD? #nephrology #nephsky #ckd #kidneydisease #healthscreening

PICKED Project

@projectpicked.bsky.social

5 days ago

DC Spotlight 🌟 Cansenem Özkan (BRFAA, PICKED)

Validating urinary & plasma protein biomarkers to predict CKD progression and monitor treatment response using multiplex mass spectrometry + peptide “signatures”.

#PICKEDproject #CKD #Biomarkers

McMaster International Review Conference of Internal Medicine

@mircim.bsky.social

5 days ago

🚀 Nephrology in 2026: what’s new, what works, what’s next

AI in nephrology, new CKD drugs, lupus nephritis, preeclampsia & more — practical updates from experts from Mayo Clinic and beyond.

📅 May 9
👉 www.mircim.one

#Nephrology #CKD #MIRCIM

@gelliottservices.bsky.social

5 days ago

#MondayMotivation ✌🏾 London #indoor #outdoor #spring 🌸 #active www.gelliottservices.com Lupusfit™️ #freelance #mind #body #yoga #fitness #health #wellbeing #muscle #tone #strength #stretch #heart #exercise #goals #maintenence #consistency #Motivation General & #Lupus #raynauds #CKD #advocate

NKF Nephrology Professionals

@nkf-professionals.bsky.social

1 week ago

CaseHippo One platform for interactive learning, engagement and collaborative knowledge

City Mouse and Country Mouse: Managing Different Geographies in CKD
Explore how geography impacts access to dialysis, medications, nutrition, transportation, and interdisciplinary care delivery.

📚 bit.ly/4kYx1L3

#Nephrology #CKD #HealthEquity #CME #Medical

Current Medical Science

@currentmedscience.bsky.social

1 week ago

Porphyromonas gingivalis Induces Chronic Kidney Disease through Crosstalk between the NF-κB/NLRP3 Pathway and Ferroptosis in GMCs

This study shows that P. gingivalis induces #CKD in mice via #NFκB/#NLRP3 crosstalk & #Ferroptosis in #Mesangial cells, highlighting the contribution of #Periodontitis to CKD pathogenesis, underscoring the importance of #PeriodontalTherapy. #medsky

To read: doi.org/10.1007/s115...

Your Other Family Doctor

@yourotherfamilydr.bsky.social

1 week ago

#cats #kittens #Caturday #catsky #CatsOfBlueSky #CKD #veterinary #vetmed #veterinarymedicine #healthcare #caregivers #pets

@gelliottservices.bsky.social

1 week ago

#fridayfit ✌🏾London #indoor #outdoor #spring 🌸 #active www.gelliottservices.com Lupusfit™️ #freelance #mind #body #yoga #fitness #health #wellbeing #muscle #tone #strength #stretch #heart #exercise #goals #maintenence #consistency #Motivation General & #Lupus #raynauds #CKD #advocate #awareness

Kidney International

@kidneyint.bsky.social

1 week ago

Kidney Disease: Improving Global Outcomes (KDIGO): navigating a rapidly changing landscape

doi.org/10.1016/j.kint.2025.12.028

#OpenAccess #MedSky #NephSky #CKD #chronickidneydisease #KDIGO

Healthcare Tips - MrMed

@onlinehealthcare.bsky.social

1 week ago

Diabetes-Related Kidney Disease: Is CKD More Serious When Diabetes Is Present? Explore The Wellness Wiki by Dil, Medical Content Advisor at MrMed. Get expert insights on super-specialty healthcare, wellness tips.

Is CKD worse with diabetes? Learn why diabetic kidney disease (DKD) increases health risks and how to manage the "double diagnosis" effectively.
onlinewellnesswiki.blogspot.com/2026/03/diab...

#DiabetesManagement #CKD #KidneyHealth

Jan T Kielstein, MD

@jtkidney.bsky.social

1 week ago

My mother in law’s coffee filter featured at the Committee on Health of the #Bundestag.
When your coffe filter rips you have grinds in the cup - if your kidney filter breaks you have albumin in the urine. The #UACR is easy to do, cost effective and helps to diagnose #CKD (chronic kidney disease).

@gelliottservices.bsky.social

1 week ago

#thursdaytone ✋🏿🙏🏾London Hospital Lupus💜Life: Stage 4>End stage Kidney Disease & #outdoor #spring 🌸 #active www.gelliottservices.com Lupusfit™️ #freelance #mind #body #yoga #fitness #health #wellbeing #muscle & #heart #exercise #goals #Motivation General & #Lupus #raynauds #CKD #advocate #awareness

PICKED Project

@projectpicked.bsky.social

1 week ago

🩹🫘 Fibrosis in kidney disease = scarring.

Repeated injury → “repair patch” → scar tissue replaces healthy tissue.
Scar tissue can’t filter blood → higher CKD progression risk.

#CKD #Fibrosis #KidneyHealth #Biomarkers #PICKEDproject